Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 10, 2019 13:03 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical, Inc. Announces Stockholder Approval of Merger Agreement with NeuBase Therapeutics, Inc.

NEW YORK, July 10, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (“Ohr”) (Nasdaq: OHRP) today announced that all proposals related to its proposed merger with NeuBase Therapeutics, Inc....
July 03, 2019 10:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Urges Stockholders to Vote “FOR” Merger with NeuBase Therapeutics at Special Meeting on July 10, 2019

-- Of the Votes Received to Date, More than 99% Are Voting in Favor of the Merger Proposal-- More Votes Are Needed to Reach 50% of the Outstanding Shares to Go Forward with the Special Meeting-- Every...
May 15, 2019 16:01 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Reports Financial Results for the Fiscal Second Quarter of 2019

NEW YORK, May 15, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) (the “Company” or “Ohr”) today reported financial results for the three and six month periods ended March 31, 2019....
February 21, 2019 10:45 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Regains Compliance with NASDAQ Listing Requirements

NEW YORK, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) today announced that it received notice from The Nasdaq Stock Market LLC indicating that the Company has regained...
February 14, 2019 16:05 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Reports Financial Results for the Fiscal First Quarter of 2019

NEW YORK, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) (the “Company” or “Ohr”) today reported financial results for the three months ended December 31, 2018. “Since we...
January 23, 2019 16:30 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Announces Reverse Stock Split to be Effective February 4, 2019

NEW YORK, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (“Ohr” or the “Company”) (Nasdaq: OHRP) announced today that its board of directors has determined to effect a one-for-twenty...
January 03, 2019 06:30 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical, Inc. Announces Merger Agreement with NeuBase Therapeutics, Inc.

Proposed combined company's peptide-nucleic acid antisense oligonucleotide (PATrOL™) technology platform enables rapid development of therapies delivered systemically for genetic diseases Initial...
August 14, 2018 16:05 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Reports Fiscal Third Quarter 2018 Financial Results

NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP), a pharmaceutical company developing therapies for ophthalmic diseases, today reported financial results for its...
May 15, 2018 16:05 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Reports Fiscal Second Quarter 2018 Financial Results

NEW YORK, May 15, 2018 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a pharmaceutical company developing therapies for ophthalmic diseases, today reported financial results for its...
February 14, 2018 16:05 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Reports Fiscal First Quarter 2018 Financial Results

NEW YORK, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a pharmaceutical company developing therapies for ophthalmic diseases, today reported financial results and...